Pharmacological inhibition of CatS with selective inhibitor RO5459072 was considered as a promising approach for alleviating ocular symptoms of Sjögren’s syndrome; however, its evaluation did not pass phase II clinical trial [37]. This evidence concerns the gene PIMREG and Sjogren syndrome.